# Bindwell landing-page growth score

Lazyweb publishes a public search API over its indexed pages; the guide is at https://www.lazyweb.com/agent-access.

Source: https://www.lazyweb.com/yc-w25/bindwell
Source observed: 2026-10-15T20:38:44.953Z
Last checked: 2026-10-20T08:28:18.593+00:00
Indexed: 2026-10-16T00:06:16.746+00:00

---

# Bindwell landing-page growth score

We provide this Lazyweb Growth Score report for [Bindwell](https://www.bindwell.ai/), a YC W25 company. The report evaluates the Bindwell landing page against biotech and drug-discovery companies and identifies **CTA** as its weakest area.

## Overall score and ranking

- **Growth score:** 28/100
- **Updated:** September 22, 2026
- **Weakest area:** CTA
- **Overall ranking:** #6 among the six compared sites

### How Bindwell ranks

1. [Charm Therapeutics — 57](https://www.lazyweb.com/growth-score/site/charmtx.com)
2. [Micropep Technologies — 56](https://www.lazyweb.com/growth-score/site/micro-pep.com)
3. [Insilico Medicine — 54](https://www.lazyweb.com/growth-score/site/insilico.com)
4. [Iambic Therapeutics — 52](https://www.lazyweb.com/growth-score/site/iambic.ai)
5. [AgPlenus — 49](https://www.lazyweb.com/growth-score/site/agplenus.com)
6. Bindwell — 28

[Fix CTA](https://www.lazyweb.com/plans/checkout?plan=individual&source=growth_score_feature_build_fixes)

## Category scores

| Category | Score | Rating |
| --- | ---: | --- |
| [CTA](https://www.lazyweb.com/yc-w25/bindwell#gs-cta) | 15 | Poor |
| [Value props](https://www.lazyweb.com/yc-w25/bindwell#gs-value_props) | 18 | Poor |
| [Trust](https://www.lazyweb.com/yc-w25/bindwell#gs-trust) | 30 | Poor |
| [Information hierarchy](https://www.lazyweb.com/yc-w25/bindwell#gs-information_hierarchy) | 38 | Poor |
| [Mobile web](https://www.lazyweb.com/yc-w25/bindwell#gs-mobile_web) | 38 | Poor |

## Score over time

- **September 22, 2026:** 28, live report; overall −35, CTA −43, Value props −40.
- [**June 17, 2026:** 63; overall +1, Mobile web +8, Trust −2](https://www.lazyweb.com/growth-score/history/2026-06-17)
- [**April 20, 2026:** 62; no score movement](https://www.lazyweb.com/growth-score/history/2026-04-20)
- [**April 10, 2026:** 62; first tracked report, strongest Trust 68, weakest Information hierarchy 58](https://www.lazyweb.com/growth-score/history/2026-04-10)

## CTA — 15, Poor

We evaluate copy, size, verb, and cost-feel to determine whether the primary CTA earns the click. The report finds:

- No CTA anywhere in the fold.
- No navigation or secondary link either.
- The fold contains only a logo and graphic.

For comparison, the other pages show **“Watch video”** for Micropep Technologies, **“REGISTER NOW!”** for Insilico Medicine, **“Discover”** for Charm Therapeutics, and **“LEARN MORE ABOUT OUR INNOVATION”** for AgPlenus.

### CTA ranking

1. Micropep Technologies — 62
2. Insilico Medicine — 44
3. Charm Therapeutics — 44
4. AgPlenus — 42
5. Iambic Therapeutics — 42
6. Bindwell — 15

[Rewrite this CTA](https://www.lazyweb.com/backlog?site=bindwell.ai#opt-cta-writing) to generate primary and secondary options grounded in Bindwell’s offer and visitor objections.

## Value props — 18, Poor

Bindwell’s headline is simply:

> “Bindwell”

### Working

- Clean, memorable brand presentation.
- Protein visual signals the biotech domain.

### Could improve

- No value claim appears anywhere in the fold.
- No subhead, proof, or numbers.
- The visual decorates rather than demonstrates.

### Value-prop ranking

1. Charm Therapeutics — 68
2. Insilico Medicine — 64
3. Iambic Therapeutics — 54
4. AgPlenus — 52
5. Micropep Technologies — 42
6. Bindwell — 18

## Trust — 30, Poor

We assess trust through proof that the product is real, competent, and safe to try.

![Insilico Medicine trust comparison](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/insilico.com.jpg?v=2026-09-22T18%3A40%3A33.219%2B00%3A00)

![Charm Therapeutics trust comparison](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/charmtx.com.jpg?v=2026-09-22T20%3A07%3A04.884%2B00%3A00)

![AgPlenus mobile trust comparison](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/agplenus.com-mobile.jpg?v=2026-09-22T20%3A04%3A08.426%2B00%3A00)

The comparison trust reads are:

| Company | Trust read |
| --- | --- |
| Bindwell | No visible trust signal identified. |
| AgPlenus | “Our Innovation” list detailing the platform: “Scanning billions of compounds”, “De novo design of small molecules” |
| Insilico Medicine | Pipeline table rows showing “Out-licensed to Exelixis” and “Out-licensed to Menarini” with Phase I–III progress bars and … |
| Micropep Technologies | No visible trust signal identified. |
| Iambic Therapeutics | No visible trust signal identified. |
| Charm Therapeutics | Headline “Addressing resistance in AML with a best-in-class menin inhibitor” naming a specific target and indication |

### Trust ranking

1. Insilico Medicine — 72
2. Charm Therapeutics — 52
3. AgPlenus — 44
4. Iambic Therapeutics — 42
5. Micropep Technologies — 38
6. Bindwell — 30

[Build proof section](https://www.lazyweb.com/backlog?site=bindwell.ai#opt-trust-signals) — choose proof signals and get copy and placement for a stronger trust section.

## Information hierarchy — 38, Poor

![Bindwell information-hierarchy annotations](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/bindwell.ai.jpg?v=2026-09-22T20%3A02%3A54.061%2B00%3A00)

1. **Bindwell wordmark:** It stands alone with no headline, subtitle, or CTA; the fold communicates a name and nothing else.
2. **Protein ribbon illustration:** The visual anchor hints at biology but carries the entire message without a caption or claim to explain it.

[View layout plan](https://www.lazyweb.com/backlog?site=bindwell.ai#opt-information-hierarchy) to turn the callouts into a sequenced keep, move, merge, or remove plan.

## Mobile web — 38, Poor

![Bindwell mobile web annotations](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/bindwell.ai-mobile.jpg?v=2026-09-22T20%3A02%3A54.061%2B00%3A00)

1. **Bindwell wordmark:** It is the only text in the fold; no value statement or CTA accompanies it, leaving visitors with nothing to act on.
2. **Protein visualization:** A decorative graphic occupies the center of the fold without communicating what Bindwell does or linking anywhere.

[View mobile fixes](https://www.lazyweb.com/backlog?site=bindwell.ai#opt-mobile-web) to convert the findings into a prioritized implementation checklist.

## Competitors

The comparison is inferred from product, audience, and value proposition.

1. [Charm Therapeutics — charmtx.com — 57](https://www.lazyweb.com/growth-score/site/charmtx.com)
2. [Micropep Technologies — micro-pep.com — 56](https://www.lazyweb.com/growth-score/site/micro-pep.com)
3. [Insilico Medicine — insilico.com — 54](https://www.lazyweb.com/growth-score/site/insilico.com)
4. [Iambic Therapeutics — iambic.ai — 52](https://www.lazyweb.com/growth-score/site/iambic.ai)
5. [AgPlenus — agplenus.com — 49](https://www.lazyweb.com/growth-score/site/agplenus.com)
6. Bindwell — 28

---

[Read this page’s summary](https://www.lazyweb.com/api/public/v1/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-w25%2Fbindwell&trace=t_bc7e1c4e5b07)

## Ask a follow-up about this page

Need a more specific answer? Ask the exact question you have. It returns a fresh, cited answer from Lazyweb’s knowledge base. No account or API key required.

Open this URL with your own question, URL-encoded. Only q is required. No account or setup.

`GET https://www.lazyweb.com/agent/faq?q={question}&trace=t_bc7e1c4e5b07`

[Tool guide and examples](https://www.lazyweb.com/agent-access) · [OpenAPI](https://www.lazyweb.com/api/public/v1/openapi.json) · [Page TLDR form](https://www.lazyweb.com/agent-tools/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-w25%2Fbindwell). Opening a form does not execute a tool.